{
  "input": {
    "mode": "report_and_evolve",
    "query": {
      "entity": "Familial tumour syndromes of the central and peripheral nervous system",
      "relation": "contraindication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_cyclophosphamide",
          "name": "Cyclophosphamide"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_doxorubicin",
          "name": "Doxorubicin"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_temozolomide",
          "name": "Temozolomide"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_vincristine",
          "name": "Vincristine"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_etoposide",
          "name": "Etoposide"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_bleomycin",
          "name": "Bleomycin"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_ifosfamide",
          "name": "Ifosfamide"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_nitrosoureas",
          "name": "Nitrosoureas"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_procarbazine",
          "name": "Procarbazine"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_bortezomib",
          "name": "Bortezomib"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_thalidomide",
          "name": "Thalidomide"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "scores": [
      {
        "hypothesis_id": "H1",
        "score": 0.35,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.9,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.85
        },
        "graph_signals": {
          "support_weight": 0.75,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adverse Phenotypes",
              "pro": [
                "H1"
              ],
              "con": [
                "H2",
                "H3",
                "H4",
                "H5",
                "H6",
                "H7",
                "H8",
                "H9",
                "H10",
                "H11",
                "H12"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Cyclophosphamide已知作用于DNA，有助于肿瘤治疗"
          ],
          "safety_risk": [
            "Skeptic指出可能引发不良反应，冲突显著"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "关于Cyclophosphamide的PK/PD特性，尚未充分验证其安全性影响"
        ]
      },
      {
        "hypothesis_id": "H2",
        "score": 0.35,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.9,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.85
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adverse Phenotypes",
              "pro": [
                "H2"
              ],
              "con": [
                "H1",
                "H3",
                "H4",
                "H5",
                "H6",
                "H7",
                "H8",
                "H9",
                "H10",
                "H11",
                "H12"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Doxorubicin对拓扑异构酶II的作用有明确证据"
          ],
          "safety_risk": [
            "Skeptic指出可能引发不良反应，冲突显著"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "关于Doxorubicin的PK/PD特性，尚未充分验证其安全性影响"
        ]
      },
      {
        "hypothesis_id": "H3",
        "score": 0.35,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.9,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.85
        },
        "graph_signals": {
          "support_weight": 0.75,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adverse Phenotypes",
              "pro": [
                "H3"
              ],
              "con": [
                "H1",
                "H2",
                "H4",
                "H5",
                "H6",
                "H7",
                "H8",
                "H9",
                "H10",
                "H11",
                "H12"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Temozolomide作用于DNA的烷化作用有临床经验支持"
          ],
          "safety_risk": [
            "Skeptic指出可能引发不良反应，冲突显著"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "关于Temozolomide的PK/PD特性，尚未充分验证其安全性影响"
        ]
      },
      {
        "hypothesis_id": "H4",
        "score": 0.35,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.9,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.85
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adverse Phenotypes",
              "pro": [
                "H4"
              ],
              "con": [
                "H1",
                "H2",
                "H3",
                "H5",
                "H6",
                "H7",
                "H8",
                "H9",
                "H10",
                "H11",
                "H12"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Vincristine对微管的调节机制已知"
          ],
          "safety_risk": [
            "Skeptic指出可能引发不良反应，冲突显著"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "关于Vincristine的PK/PD特性，尚未充分验证其安全性影响"
        ]
      },
      {
        "hypothesis_id": "H5",
        "score": 0.35,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.9,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.85
        },
        "graph_signals": {
          "support_weight": 0.75,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adverse Phenotypes",
              "pro": [
                "H5"
              ],
              "con": [
                "H1",
                "H2",
                "H3",
                "H4",
                "H6",
                "H7",
                "H8",
                "H9",
                "H10",
                "H11",
                "H12"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Etoposide靶向拓扑异构酶II的作用机制已知"
          ],
          "safety_risk": [
            "Skeptic指出可能引发不良反应，冲突显著"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "关于Etoposide的PK/PD特性，尚未充分验证其安全性影响"
        ]
      },
      {
        "hypothesis_id": "H6",
        "score": 0.35,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.9,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.85
        },
        "graph_signals": {
          "support_weight": 0.65,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adverse Phenotypes",
              "pro": [
                "H6"
              ],
              "con": [
                "H1",
                "H2",
                "H3",
                "H4",
                "H5",
                "H7",
                "H8",
                "H9",
                "H10",
                "H11",
                "H12"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Bleomycin对DNA的损伤作用验证过"
          ],
          "safety_risk": [
            "Skeptic指出可能引发不良反应，冲突显著"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "关于Bleomycin的PK/PD特性，尚未充分验证其安全性影响"
        ]
      },
      {
        "hypothesis_id": "H7",
        "score": 0.35,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.9,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.85
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adverse Phenotypes",
              "pro": [
                "H7"
              ],
              "con": [
                "H1",
                "H2",
                "H3",
                "H4",
                "H5",
                "H6",
                "H8",
                "H9",
                "H10",
                "H11",
                "H12"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Ifosfamide在特征上类似于Cyclophosphamide"
          ],
          "safety_risk": [
            "Skeptic指出可能引发不良反应，冲突显著"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "关于Ifosfamide的PK/PD特性，尚未充分验证其安全性影响"
        ]
      },
      {
        "hypothesis_id": "H8",
        "score": 0.35,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.9,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.85
        },
        "graph_signals": {
          "support_weight": 0.65,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adverse Phenotypes",
              "pro": [
                "H8"
              ],
              "con": [
                "H1",
                "H2",
                "H3",
                "H4",
                "H5",
                "H6",
                "H7",
                "H9",
                "H10",
                "H11",
                "H12"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Nitrosoureas用于治疗脑肿瘤有一定传统"
          ],
          "safety_risk": [
            "Skeptic指出可能引发不良反应，冲突显著"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "关于Nitrosoureas的PK/PD特性，尚未充分验证其安全性影响"
        ]
      },
      {
        "hypothesis_id": "H9",
        "score": 0.35,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.9,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.85
        },
        "graph_signals": {
          "support_weight": 0.6,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adverse Phenotypes",
              "pro": [
                "H9"
              ],
              "con": [
                "H1",
                "H2",
                "H3",
                "H4",
                "H5",
                "H6",
                "H7",
                "H8",
                "H10",
                "H11",
                "H12"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Methotrexate与神经系统的不良反应有已知相关性"
          ],
          "safety_risk": [
            "Skeptic指出可能引发不良反应，冲突显著"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "关于Methotrexate的PK/PD特性，尚未充分验证其安全性影响"
        ]
      },
      {
        "hypothesis_id": "H10",
        "score": 0.35,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.9,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.85
        },
        "graph_signals": {
          "support_weight": 0.55,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adverse Phenotypes",
              "pro": [
                "H10"
              ],
              "con": [
                "H1",
                "H2",
                "H3",
                "H4",
                "H5",
                "H6",
                "H7",
                "H8",
                "H9",
                "H11",
                "H12"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Procarbazine在肿瘤治疗上有传统"
          ],
          "safety_risk": [
            "Skeptic指出可能引发不良反应，冲突显著"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "关于Procarbazine的PK/PD特性，尚未充分验证其安全性影响"
        ]
      },
      {
        "hypothesis_id": "H11",
        "score": 0.35,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.9,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.85
        },
        "graph_signals": {
          "support_weight": 0.5,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adverse Phenotypes",
              "pro": [
                "H11"
              ],
              "con": [
                "H1",
                "H2",
                "H3",
                "H4",
                "H5",
                "H6",
                "H7",
                "H8",
                "H9",
                "H10",
                "H12"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Bortezomib对凋亡通路有明确作用机制"
          ],
          "safety_risk": [
            "Skeptic指出可能引发不良反应，冲突显著"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "关于Bortezomib的PK/PD特性，尚未充分验证其安全性影响"
        ]
      },
      {
        "hypothesis_id": "H12",
        "score": 0.35,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.9,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.85
        },
        "graph_signals": {
          "support_weight": 0.5,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adverse Phenotypes",
              "pro": [
                "H12"
              ],
              "con": [
                "H1",
                "H2",
                "H3",
                "H4",
                "H5",
                "H6",
                "H7",
                "H8",
                "H9",
                "H10",
                "H11"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Thalidomide可能导致已知的神经毒性"
          ],
          "safety_risk": [
            "Skeptic指出可能引发不良反应，冲突显著"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "关于Thalidomide的PK/PD特性，尚未充分验证其安全性影响"
        ]
      }
    ],
    "ranking": [
      "H1",
      "H2",
      "H3",
      "H4",
      "H5",
      "H6",
      "H7",
      "H8",
      "H9",
      "H10",
      "H11",
      "H12"
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "n_target1",
          "type": "Target",
          "label": "DNA",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_target2",
          "type": "Target",
          "label": "Topoisomerase II",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_pathway1",
          "type": "Pathway",
          "label": "Apoptosis Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_pathway2",
          "type": "Pathway",
          "label": "Cell Cycle Arrest Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_disease",
          "type": "Disease",
          "label": "Familial Tumour Syndromes",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ph1",
          "type": "Phenotype",
          "label": "Tumor Growth",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ph2",
          "type": "Phenotype",
          "label": "Neurotoxicity",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_cyclophosphamide",
          "type": "Drug",
          "label": "Cyclophosphamide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_doxorubicin",
          "type": "Drug",
          "label": "Doxorubicin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_temozolomide",
          "type": "Drug",
          "label": "Temozolomide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_vincristine",
          "type": "Drug",
          "label": "Vincristine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_etoposide",
          "type": "Drug",
          "label": "Etoposide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_bleomycin",
          "type": "Drug",
          "label": "Bleomycin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ifosfamide",
          "type": "Drug",
          "label": "Ifosfamide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_nitrosoureas",
          "type": "Drug",
          "label": "Nitrosoureas",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_procarbazine",
          "type": "Drug",
          "label": "Procarbazine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_bortezomib",
          "type": "Drug",
          "label": "Bortezomib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_thalidomide",
          "type": "Drug",
          "label": "Thalidomide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot",
          "type": "Target",
          "label": "OffTarget",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp",
          "type": "Pathway",
          "label": "Risk Pathway",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_advPhenotype",
          "type": "Phenotype",
          "label": "Adverse Phenotype",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Cyclophosphamide",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_cyclophosphamide",
          "type": "Drug",
          "label": "Cyclophosphamide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Doxorubicin",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_doxorubicin",
          "type": "Drug",
          "label": "Doxorubicin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Temozolomide",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_temozolomide",
          "type": "Drug",
          "label": "Temozolomide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Vincristine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_vincristine",
          "type": "Drug",
          "label": "Vincristine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Etoposide",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_etoposide",
          "type": "Drug",
          "label": "Etoposide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Bleomycin",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_bleomycin",
          "type": "Drug",
          "label": "Bleomycin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Ifosfamide",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_ifosfamide",
          "type": "Drug",
          "label": "Ifosfamide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Nitrosoureas",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_nitrosoureas",
          "type": "Drug",
          "label": "Nitrosoureas",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Methotrexate",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Procarbazine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_procarbazine",
          "type": "Drug",
          "label": "Procarbazine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Bortezomib",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_bortezomib",
          "type": "Drug",
          "label": "Bortezomib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Thalidomide",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_thalidomide",
          "type": "Drug",
          "label": "Thalidomide",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_cyclophosphamide",
          "target": "n_target1",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "已知氮芥类药物作用于DNA"
        },
        {
          "source": "drug_doxorubicin",
          "target": "n_target2",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "已有实验证据支持其与拓扑异构酶 II 结合"
        },
        {
          "source": "n_target1",
          "target": "n_pathway1",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "DNA损伤通路与细胞凋亡密切相关"
        },
        {
          "source": "n_target2",
          "target": "n_pathway2",
          "relation": "involved_in",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "拓扑异构酶 II 在细胞周期调控中起重要作用"
        },
        {
          "source": "n_pathway1",
          "target": "n_ph1",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "细胞凋亡直接导致肿瘤生长抑制"
        },
        {
          "source": "n_pathway2",
          "target": "n_ph2",
          "relation": "causes",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "细胞周期停滞可引发神经毒性"
        },
        {
          "source": "drug_temozolomide",
          "target": "n_target1",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "常用于胶质瘤的DNA烷化剂"
        },
        {
          "source": "drug_vincristine",
          "target": "n_pathway2",
          "relation": "modulates",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "已知抑制微管聚合引起细胞周期停滞"
        },
        {
          "source": "drug_etoposide",
          "target": "n_target2",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "靶向拓扑异构酶 II 的经典药物"
        },
        {
          "source": "drug_bleomycin",
          "target": "n_target1",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "已知导致DNA单链断裂"
        },
        {
          "source": "drug_ifosfamide",
          "target": "n_target1",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "类似于环磷酰胺，影响DNA"
        },
        {
          "source": "drug_nitrosoureas",
          "target": "n_target1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "常用于脑肿瘤治疗的药物"
        },
        {
          "source": "drug_methotrexate",
          "target": "n_ph2",
          "relation": "modulates",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "已知与神经系统相关的副作用"
        },
        {
          "source": "drug_procarbazine",
          "target": "n_ph1",
          "relation": "causes",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "与肿瘤生长相关临床发现"
        },
        {
          "source": "drug_bortezomib",
          "target": "n_pathway1",
          "relation": "modulates",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "已知影响凋亡通路"
        },
        {
          "source": "drug_thalidomide",
          "target": "n_ph2",
          "relation": "causes",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "可能导致神经毒性"
        },
        {
          "source": "drug_cyclophosphamide",
          "target": "H1",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "机制支持对肿瘤的影响"
        },
        {
          "source": "drug_doxorubicin",
          "target": "H2",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "对特定肿瘤类型有效的已知反应"
        },
        {
          "source": "drug_temozolomide",
          "target": "H3",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "对胶质瘤的有效性已知"
        },
        {
          "source": "drug_vincristine",
          "target": "H4",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "与细胞周期影响相关已知"
        },
        {
          "source": "drug_etoposide",
          "target": "H5",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "与细胞周期及肿瘤抑制作用相关"
        },
        {
          "source": "drug_bleomycin",
          "target": "H6",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "与重要的DNA损伤机制相关"
        },
        {
          "source": "drug_ifosfamide",
          "target": "H7",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "剽窃与环磷酰胺的药理关联"
        },
        {
          "source": "drug_nitrosoureas",
          "target": "H8",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "与类似肿瘤治疗药物响应一致"
        },
        {
          "source": "drug_methotrexate",
          "target": "H9",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "与潜在的神经影响有关"
        },
        {
          "source": "drug_procarbazine",
          "target": "H10",
          "relation": "supports",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "与预期肿瘤干预相关"
        },
        {
          "source": "drug_bortezomib",
          "target": "H11",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "可能涉及不同的机制"
        },
        {
          "source": "drug_thalidomide",
          "target": "H12",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "相关的潜在风险与神经影响"
        },
        {
          "source": "n_cyclophosphamide",
          "target": "n_ot",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "可能作用于非靶点，引发风险"
        },
        {
          "source": "n_doxorubicin",
          "target": "n_ot",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "可能作用于非靶点，引发风险"
        },
        {
          "source": "n_temozolomide",
          "target": "n_ot",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能作用于非靶点，引发风险"
        },
        {
          "source": "n_vincristine",
          "target": "n_ot",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能作用于非靶点，引发风险"
        },
        {
          "source": "n_etoposide",
          "target": "n_ot",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能作用于非靶点，引发风险"
        },
        {
          "source": "n_bleomycin",
          "target": "n_ot",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能作用于非靶点，引发风险"
        },
        {
          "source": "n_ifosfamide",
          "target": "n_ot",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Skeptic",
          "rationale": "可能作用于非靶点，引发风险"
        },
        {
          "source": "n_nitrosoureas",
          "target": "n_ot",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Skeptic",
          "rationale": "可能作用于非靶点，引发风险"
        },
        {
          "source": "n_methotrexate",
          "target": "n_ot",
          "relation": "acts_on",
          "weight": 0.5,
          "agent": "Skeptic",
          "rationale": "可能作用于非靶点，引发风险"
        },
        {
          "source": "n_procarbazine",
          "target": "n_ot",
          "relation": "acts_on",
          "weight": 0.5,
          "agent": "Skeptic",
          "rationale": "可能作用于非靶点，引发风险"
        },
        {
          "source": "n_bortezomib",
          "target": "n_ot",
          "relation": "acts_on",
          "weight": 0.5,
          "agent": "Skeptic",
          "rationale": "可能作用于非靶点，引发风险"
        },
        {
          "source": "n_thalidomide",
          "target": "n_ot",
          "relation": "acts_on",
          "weight": 0.5,
          "agent": "Skeptic",
          "rationale": "可能作用于非靶点，引发风险"
        },
        {
          "source": "n_ot",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "引发相关风险通路"
        },
        {
          "source": "n_rp",
          "target": "n_advPhenotype",
          "relation": "causes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "导致不良反应"
        },
        {
          "source": "n_advPhenotype",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消 Cyclophosphamide 的净获益"
        },
        {
          "source": "n_advPhenotype",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消 Doxorubicin 的净获益"
        },
        {
          "source": "n_advPhenotype",
          "target": "H3",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消 Temozolomide 的净获益"
        },
        {
          "source": "n_advPhenotype",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消 Vincristine 的净获益"
        },
        {
          "source": "n_advPhenotype",
          "target": "H5",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消 Etoposide 的净获益"
        },
        {
          "source": "n_advPhenotype",
          "target": "H6",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消 Bleomycin 的净获益"
        },
        {
          "source": "n_advPhenotype",
          "target": "H7",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消 Ifosfamide 的净获益"
        },
        {
          "source": "n_advPhenotype",
          "target": "H8",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消 Nitrosoureas 的净获益"
        },
        {
          "source": "n_advPhenotype",
          "target": "H9",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消 Methotrexate 的净获益"
        },
        {
          "source": "n_advPhenotype",
          "target": "H10",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消 Procarbazine 的净获益"
        },
        {
          "source": "n_advPhenotype",
          "target": "H11",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消 Bortezomib 的净获益"
        },
        {
          "source": "n_advPhenotype",
          "target": "H12",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消 Thalidomide 的净获益"
        }
      ],
      "round_index": 2
    },
    "history": {
      "round": 2
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_cyclophosphamide",
          "name": "Cyclophosphamide"
        },
        "score": 0.35,
        "graph_snapshot_ref": "GE_H1_round3",
        "key_assumptions": [
          "Cyclophosphamide 的PK/PD特性仍需验证",
          "不良反应可能抵消其对肿瘤的治疗益处"
        ],
        "caveats": [
          "Skeptic 强调的安全性风险显著"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_doxorubicin",
          "name": "Doxorubicin"
        },
        "score": 0.35,
        "graph_snapshot_ref": "GE_H2_round3",
        "key_assumptions": [
          "Doxorubicin 的作用机制与拓扑异构酶 II 有效结合",
          "潜在的安全性问题仍需关注"
        ],
        "caveats": [
          "Skeptic 提出的不良反应有显著影响"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_temozolomide",
          "name": "Temozolomide"
        },
        "score": 0.35,
        "graph_snapshot_ref": "GE_H3_round3",
        "key_assumptions": [
          "Temozolomide 具有明确的作用机制",
          "相应的安全性问题需被重视"
        ],
        "caveats": [
          "可能的不良反应需要进一步评估"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "多个药物作用于相同靶点，增加了不良反应的潜在风险",
          "reason": "每个药物的影响在图中均涉及 \"不良表型\" 的相互作用"
        }
      ],
      "remaining_gaps": [
        "需要更详细的数据和证据来验证每种药物的PK/PD特性和安全性问题"
      ]
    },
    "seed_retrospective": {
      "batches": [],
      "lessons": []
    },
    "prompt_patches": [],
    "heuristics": []
  }
}